Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24214 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL1356717 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL5448 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL6654323 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL15952 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL213208 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL3690123 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL3834 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL10262394 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL15665811 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238200-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240189231-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS REASEARCH INC. (CA) | 2024-06-13 | — | — | US | disclosed |
| US-20230157954-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS REASEARCH INC. (CA) | 2023-05-25 | — | — | US | disclosed |
| US-20230143474-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS REASEARCH INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| WO-2021056106-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2021-04-01 | — | — | WO | disclosed |
| US-20020098440-A1 | Positive photoresist composition for far ultraviolet ray exposure | FUJIFILM CORPORATION (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6383471-B1 | DRUG DELIVERY | LIPOCINE, INC. | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238200-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | PRKCA 3876/4885MAPT 4570/4885MAPK1 4136/4885 |
| US-20230143474-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | PRKCA 3876/4885MAPT 4570/4885MAPK1 4136/4885 |
| US-20240189231-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | PRKCA 3876/4885MAPT 4570/4885MAPK1 4136/4885 |
| US-20230157954-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | PRKCA 3876/4885MAPT 4570/4885MAPK1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.